Sugi Predict

Sugi Predict / Compounds / SCHEMBL3973764

SCHEMBL3973764

SCHEMBL3973764

O=Cc1c(F)cccc1B(O)O

nearest known ligand 0.54

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ ERN1 O75460 1/20 0.47
▸ NFE2L2 Q16236 2/20 0.39
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ CES2 O00748 1/20 0.35
▸ CES1 P23141 1/20 0.35
▸ ABCG2 Q9UNQ0 1/20 0.35
▸ IKBKB O14920 1/20 0.34
▸ NOTUM Q6P988 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31396936 1.00 ERN1 (0.47) ERN1NFE2L2MEN1ALDH1A1KMT2A
SCHEMBL3426311 0.79 MEN1 (0.44) ERN1MEN1ALDH1A1KMT2ATDP1
SCHEMBL95708 0.78 ERN1 (0.50) ERN1NFE2L2MEN1ALDH1A1KMT2A
SCHEMBL6208275 0.78 ALDH1A1 (0.45) ERN1MEN1ALDH1A1KMT2ATDP1
SCHEMBL1786706 0.76 CYP2C9 (0.41) ERN1
SCHEMBL29895193 0.76 CYP2C9 (0.41) ERN1
SCHEMBL31026008 0.76 ERN1 (0.38) ERN1CES2CES1
SCHEMBL28576204 0.76 ERN1 (0.41) ERN1MEN1ALDH1A1KMT2ATDP1
SCHEMBL1984475 0.76 ALDH1A1 (0.61) MEN1ALDH1A1KMT2ATDP1SMN1; SMN2
SCHEMBL31614953 0.76 ERN1 (0.41) ERN1MEN1ALDH1A1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115975224-B pH/ROS double-response tissue adhesion carrier hydrogel and preparation method and application thereof 四川大学 2023-08-08 — — CN claimed
CN-115975224-A PH/ROS dual-response tissue adhesion drug-loaded hydrogel and preparation method and application thereof 四川大学 2023-04-18 — — CN claimed
CN-106946918-B Asymmetric naphthalene nucleus condenses two pyrroles's fluorescent dye of fluorine boron and preparation method thereof 江苏科技大学 2019-08-09 — — CN claimed
US-20260008767-A1 SOMATOSTATIN MODULATORS AND USES THEREOF CRINETICS PHARMACEUTICALS INC (US) 2026-01-08 — — US disclosed
WO-2024220541-A1 NK3 MODULATORS AND USES THEREOF KALLYOPE, INC. (US) 2024-10-24 — — WO disclosed
WO-2024163405-A1 BORON CONTAINING COMPOUNDS AND THEIR USES 5METIS, INC. (US) 2024-08-08 — — WO disclosed
CN-111377974-B Organometallic compound and organic light emitting device including the same 三星电子株式会社 2024-04-23 — — CN disclosed
CN-117460698-A Surface-modified nanoparticles 国立大学法人京都大学 2024-01-26 — — CN disclosed
US-20230397488-A1 ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO LTD (KR) 2023-12-07 — — US disclosed
US-11800788-B2 Organometallic compound and organic light-emitting device including i he same SAMSUNG ELECTRONICS CO., LTD. (KR) 2023-10-24 — — US disclosed
CN-115975224-B pH/ROS double-response tissue adhesion carrier hydrogel and preparation method and application thereof 四川大学 2023-08-08 — — CN disclosed
WO-2018175954-A1 SYNTHESIS OF IMIDAZO[5,1-A]ISOINDOLE DERIVATIVE USEFUL AS IDO INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2018-09-27 — — WO disclosed
US-9896432-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2018-02-20 — — US disclosed
WO-2018028491-A1 INDOLEAMINE2,3-DIOXYGENASE INHIBITORS AND USES THEREOF IN PHARMACY 苏州国匡医药科技有限公司 2018-02-15 — — WO disclosed
WO-2018013676-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2018-01-18 — — WO disclosed
US-20180016252-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2018-01-18 — — US disclosed
CN-107176956-A A kind of IDO inhibitor compound, Pharmaceutical composition, purposes 成都海博锐药业有限公司 2017-09-19 — — CN disclosed
WO-2013084198-A1 CHEMICAL MODIFICATION AND BIOCONJUGATION OF PROTEINS OR PEPTIDES USING BORON COMPOUNDS UNIVERSIDADE DE LISBOA (PT) 2013-06-13 — — WO disclosed
WO-2013084198-A1 CHEMICAL MODIFICATION AND BIOCONJUGATION OF PROTEINS OR PEPTIDES USING BORON COMPOUNDS UNIVERSIDADE DE LISBOA (PT) 2013-06-13 — — WO disclosed
WO-2009051417-A2 PHENANTHRENE LACTAM DERIVATIVES HAVING ANTICANCER ACTIVITY AND METHOD FOR THE PREPARATION THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2009-04-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11800788-B2 Organometallic compound and organic light-emitting device including i he same UBE2L3, CRY1, OR10J3 ERN1 1906/4885NFE2L2 44/4885MEN1 174/4885
US-20180016252-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 ERN1 2959/4885NFE2L2 4724/4885MEN1 110/4885
US-20230397488-A1 ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME OR10J3, UBE2L3, NR2E3 ERN1 2146/4885NFE2L2 17/4885MEN1 418/4885
US-20260008767-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR3, SSTR2 ERN1 2036/4885NFE2L2 3409/4885MEN1 661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.